Cite
Heestermans AA, Hermanides RS, Gosselink AT, et al. A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI: Insights from the Zwolle acute myocardial infarction registry. Neth Heart J. 2010;18(12):592-7doi: 10.1007/s12471-010-0840-z.
Heestermans, A. A., Hermanides, R. S., Gosselink, A. T., de Boer, M. J., Hoorntje, J. C., Suryapranata, H., Ottervanger, J. P., Dambrink, J. H., Kolkman, E., Ten Berg, J. M., Zijlstra, F., & van 't Hof, A. W. (2010). A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI: Insights from the Zwolle acute myocardial infarction registry. Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, 18(12), 592-7. https://doi.org/10.1007/s12471-010-0840-z
Heestermans, A A C M, et al. "A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI: Insights from the Zwolle acute myocardial infarction registry." Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation vol. 18,12 (2010): 592-7. doi: https://doi.org/10.1007/s12471-010-0840-z
Heestermans AA, Hermanides RS, Gosselink AT, de Boer MJ, Hoorntje JC, Suryapranata H, Ottervanger JP, Dambrink JH, Kolkman E, Ten Berg JM, Zijlstra F, van 't Hof AW. A comparison between upfront high-dose tirofiban versus provisional use in the real-world of non-selected STEMI patients undergoing primary PCI: Insights from the Zwolle acute myocardial infarction registry. Neth Heart J. 2010 Dec;18(12):592-7. doi: 10.1007/s12471-010-0840-z. PMID: 21301621; PMCID: PMC3018604.
Copy
Download .nbib